Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple.

Slides:

Advertisements

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Advertisements

Fig. 1. TP is highly expressed in myeloma.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Fig. 3. Structure of ALS-associated RNA binding proteins.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 4. Biomechanical properties of treated tibiae.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 1. Schematic representation of the MANO method.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Identification of bioactive compounds modulating STING activation

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5. In vivo characterization of adipogenesis by CT.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.

Fig. 4. MATE1 transcription in RCC.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 7 Human study design for device testing.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 2. DCA activates PDH and increases respiration in human PAH EVLP.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Human HFpEF is associated with impaired cardiac myofibril relaxation

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 2 ALRN-6924 rapidly increases transcription at the p21 locus and affects its bursting dynamics. ALRN-6924 rapidly increases transcription at the p21.

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Decreased weight and adiposity is transmissible via the gut microbiota

Fig. 3 Activation of freshly isolated CD4+ T cells from HIV-infected patients on ART selectively reverses baseline blocks to splicing, elongation, and.

Fig. 5 HDAC inhibition blocks age-dependent diastolic dysfunction.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 6. Eradication of FLT3-ITD+ AML cells in vivo through combined inhibition of kinase and antiapoptotic pathways. Eradication of FLT3-ITD+ AML cells.

Fig. 5 Wireless, full-body pressure mapping on a human subject in a hospital bed. Wireless, full-body pressure mapping on a human subject in a hospital.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

A precision therapy against cancers driven by KIT/PDGFRA mutations

Presentation transcript:

Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 antitumor activity in both primary and refractory KIT-driven disease models. (A to C) Antitumor activity (A), body weight (B), and PK/PD (C) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model. (D to F) Antitumor activity of BLU-285 and reference compounds (top) and pharmacodynamic analysis of KIT inhibition (bottom) in human GIST PDX models of disease with (D) KIT exon 11/17 delW557K558/Y823D, (E) KIT exon 11 delW557-V559insF, and (F) KIT exon 11/13 delW557K558/V654A mutations. QD, once daily; BID, twice daily. Erica K. Evans et al., Sci Transl Med 2017;9:eaao1690 Published by AAAS